# Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

> **NCT05003245** · PHASE3 · COMPLETED · sponsor: **Shanghai Henlius Biotech** · enrollment: 407 (actual)

## Conditions studied

- Age Related Macular Degeneration

## Interventions

- **DRUG:** HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection
- **DRUG:** Lucentis

## Key facts

- **NCT ID:** NCT05003245
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-01
- **Primary completion:** 2024-05-07
- **Final completion:** 2024-05-07
- **Target enrollment:** 407 (ACTUAL)
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05003245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05003245, "Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05003245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*